Targets › MTNR1B
30 programs from 30 companies in 34 trials: 14 Phase 2, 11 Phase 3, 8 Phase 4, 1 Phase 1; Psychiatry, Other, Neurology; next expected readout Nov 2026.
High affinity receptor for melatonin. Likely to mediate the reproductive and circadian actions of melatonin. (UniProt, P49286)
Open in Phaseline: the race on MTNR1B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Oklahoma | melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 4 | Healthy | Nov 2026 |
| Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 4 | Ischemic Stroke, Acute | Dec 2026 |
| Mahidol University | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 4 | IBD (Inflammatory Bowel Disease) | Apr 2027 |
| University Hospital, Basel, Switzerland | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 4 | Hypoactive Delirium | Dec 2027 |
| Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 4 | Obstructive Sleep Apnea of Adult | Dec 2027 |
| Massachusetts General Hospital | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 4 | Depression | Jul 2028 |
| Thammasat University | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 4 | Melasma | – |
| Al-Azhar University | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 4 | Cataract Surgery Anesthesia | – |
| Bart Koes | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 3 | Chronic Low-back Pain (cLBP) | Dec 2026 |
| Arash Afshari | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 3 | Emergence Delirium | Mar 2027 |
| Monash University | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 3 | Fetal Growth Retardation | Apr 2027 |
| Rutgers, The State University of New Jersey | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 3 | Acute Kidney Injury | Jun 2027 |
| Emory University | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 3 | Orthopedic Trauma | Jul 2027 |
| Vanda Pharmaceuticals | Tasimelteon Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 3 | Sleep Wake Disorders; Insomnia Disorder | Nov 2027 |
| Assistance Publique - Hôpitaux de Paris | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 3 | Major Depressive Disorder (MDD) With Insomnia | Aug 2028 |
| Gustav Stalhammar | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 3 | Uveal Melanoma | Jan 2031 |
| Tanta University | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 3 | Cardiomyopathies | – |
| Ain Shams University | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | Comparative Effectiveness; Diabetic Peripheral Neuropathy | Dec 2026 |
| Leslie Swanson | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | Bipolar Disorder | Dec 2026 |
| Ciusss de L'Est de l'Île de Montréal | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | Delirium | Dec 2026 |
| M.D. Anderson Cancer Center | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | Sleep; Hematopoietic and Lymphoid Cell Neoplasm | Feb 2027 |
| Beni-Suef University | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | Ureteral Stent-Related Symptoms | Apr 2027 |
| University Hospital, Strasbourg, France | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | Idiopathic Hypersomnia | Sep 2027 |
| Lars Vedel Kessing | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | Bipolar Affective Disorder | Jun 2028 |
| Lone Baandrup | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | Psychiatric Disorders | Feb 2029 |
| University of Illinois Chicago | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | Diabetes Mellitus | – |
| University of Child Health Sciences and Children's Hospital, Lahore | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | Hypoxic Ischaemic Encephalopathy (HIE) | – |
| Benha University | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | ICS | – |
| Sultan Qaboos University | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 2 | Delirium | – |
| Mian Muhammad Hassan Ahmed | Melatonin Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 1 | Pneumonia Childhood | – |
Sleep Wake Disorders (2) Delirium (2) Insomnia Disorder (1) Chronic Low-back Pain (cLBP) (1) Major Depressive Disorder (MDD) With Insomnia (1) Diabetes Mellitus (1) Depression (1) Hypoxic Ischaemic Encephalopathy (HIE) (1) ICS (1) Ureteral Stent-Related Symptoms (1) Sleep (1) Hematopoietic and Lymphoid Cell Neoplasm (1)
small molecule (26)
Vanda Pharmaceuticals (1) Bart Koes (1) Assistance Publique - Hôpitaux de Paris (1) Ciusss de L'Est de l'Île de Montréal (1) University of Illinois Chicago (1) Massachusetts General Hospital (1) University of Child Health Sciences and Children's Hospital, Lahore (1) Benha University (1) Beni-Suef University (1) M.D. Anderson Cancer Center (1) Mahidol University (1) Thammasat University (1) Mian Muhammad Hassan Ahmed (1) Monash University (1) Lars Vedel Kessing (1) Ain Shams University (1) Rutgers, The State University of New Jersey (1) Leslie Swanson (1) Al-Azhar University (1) University of Oklahoma (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.